NCT05743140 A Clinical Study of Fundus OCTA for the Identification of CMD
| NCT ID | NCT05743140 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Coronary Microvascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2025-12-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-03-01 with a primary completion date of 2025-12-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Coronary microvascular dysfunction (CMD) carries an increased risk of adverse cardiovascular clinical outcomes. The association between fundus microcirculation changes and coronary microcirculation is not well understood. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) is a new type of optical diagnostic imaging technology for non-invasive detection, which can perform multi-dimensional quantitative assessment of fundus microcirculation. In this study, investigators intend to use the coronary angiography-derived index of microvascular resistance (caIMR) to screen patients with CMD, explore the relationship between relevant parameters based on OCT and OCTA measurements and caIMR, and evaluate the feasibility and clinical value of non-invasive identification of CMD through fundus OCT and OCTA.
Eligibility Criteria
Inclusion Criteria: 1. Patients who underwent coronary angiography in the Department of Cardiology, Peking University First Hospital; 2. Complete baseline clinical information; 3. Subject who have coronary angiography results, which shows coronary stenosis \< 50%; 4. Older than 18 years; 5. Subjects who have signed informed consent. Exclusion Criteria: 1. Present serious fundus disease 2. Severe cataract and other ophthalmic diseases, which affect imaging quality; 3. Target coronary vessels provide collateral circulation for chronic complete occlusive lesions; 4. The target coronary angiography agent is poorly filled, overlapped, or severely distorted, and cannot fully expose the location of the lesion; 5. Coronary angiography images are of poor quality and cannot be identified; 6. Active bleeding state; 7. Severe renal insufficiency, contrast agent allergy, and unable to perform coronary angiography.
Contact & Investigator
Bo Zheng, Dr
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT05743140 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Microvascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05743140 currently recruiting?
Yes, NCT05743140 is actively recruiting participants. Contact the research team at zhengbopatrick@163.com for enrollment information.
Where is the NCT05743140 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05743140 clinical trial?
NCT05743140 is sponsored by Peking University First Hospital. The principal investigator is Bo Zheng, Dr at Peking University First Hospital. The trial plans to enroll 400 participants.